Brammer, J. E., Ballen, K., Sokol, L., Querfeld, C., Nakamura, R., Mishra, A., . . . Loughran, T. (2023). Effective treatment with the selective cytokine inhibitor BNZ-1 reveals the cytokine dependency of T-LGL leukemia. BLOOD, 142(15), 1271-1280. doi:10.1182/blood.2022017643

Ma, H., Loughran, T. P., & Gupta, P. (2023). An analysis of veterans diagnosed with large granular lymphocytic disorders at the national Veteran Affairs Healthcare System. AMERICAN JOURNAL OF HEMATOLOGY, 98(8), E190-E192. doi:10.1002/ajh.26948

Fisher-Wellman, K. H., Kassai, M., Hagen, J. T., Neufer, P. D., Kester, M., Loughran Jr., T. P., . . . Cabot, M. C. (2023). Simultaneous Inhibition of Ceramide Hydrolysis and Glycosylation Synergizes to Corrupt Mitochondrial Respiration and Signal Caspase Driven Cell Death in Drug-Resistant Acute Myeloid Leukemia. CANCERS, 15(6). doi:10.3390/cancers15061883

Barila, G., Grassi, A., Cheon, H., Teramo, A., Calabretto, G., Chahal, J., . . . Zambello, R. (2023). Tγδ LGLL identifies a subset with more symptomatic disease: analysis of an international cohort of 137 patients. BLOOD, 141(9), 1036-1046. doi:10.1182/blood.2021013489

Loughran, T. P., Cohn, W., Bonilla, G., & Anderson, R. T. (2022). Cancer Prevention from the Viewpoint of UVA Comprehensive Cancer Center.. Cancer prevention research (Philadelphia, Pa.), OF1-OF6. doi:10.1158/1940-6207.capr-22-0365

Khokhlatchev, A. V., Sharma, A., Deering, T. G., Shaw, J. J. P., Costa-Pinheiro, P., Golla, U., . . . Kester, M. (2022). Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia. FASEB JOURNAL, 36(10). doi:10.1096/fj.202200765R

Cheon, H., Elghawy, O., Shemo, B. C., Feith, D. J., & Loughran, T. P. (2022). LGL leukemia patients exhibit substantial protective humoral responses following SARS-CoV-2 vaccination.. EJHaem, 3(3), 919-923. doi:10.1002/jha2.472

Mundy-Bosse, B. L., Weigel, C., Wu, Y. -Z., Abdelbaky, S., Youssef, Y., Casas, S. B., . . . Oakes, C. C. (2022). Identification and Targeting of the Developmental Blockade in Extranodal Natural Killer/T-cell Lymphoma. BLOOD CANCER DISCOVERY, 3(2), 154-169. doi:10.1158/2643-3230.BCD-21-0098

Loughran Jr, T. P., Cohn, W., Bonilla, G., & Anderson, R. T. (2022). Cancer Prevention from the Viewpoint of UVA Comprehensive Cancer Center. CANCER PREVENTION RESEARCH, 15(11), 715-720. doi:10.1158/1940-6207.CAPR-22-0365

Ung, J., Tan, S. -F., Shaw, J., Fox, T., Kester, M., Feith, D., & Loughran, T. J. (2022). Superior Anti-Leukemic Effects of Combined Acid Ceramidase and Bcl-2 Inhibition in Acute Myeloid Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 22, S211-S212.

LeBlanc, F. R., Hasanali, Z. S., Stuart, A., Shimko, S., Sharma, K., Leshchenko, V. V., . . . Epner, E. M. (2022). Combined epigenetic and immunotherapy for blastic and classical mantle cell lymphoma.. Oncotarget, 13, 986-1002. doi:10.18632/oncotarget.28258

Fries, C., Evans, A. G., Cheon, H., Korones, D. N., Loughran, T. P. J., & Andolina, J. R. (2022). Allogeneic Bone Marrow Transplant as a Cure for Refractory T-Cell Large Granular Lymphocytic Leukemia in an Adolescent. JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 44(6), E960-E963. doi:10.1097/MPH.0000000000002390

Moosic, K. B., Ananth, K., Andrade, F., Feith, D. J., Darrah, E., & Loughran, T. P. (2022). Intersection Between Large Granular Lymphocyte Leukemia and Rheumatoid Arthritis. FRONTIERS IN ONCOLOGY, 12. doi:10.3389/fonc.2022.869205

Baer, C., Kimura, S., Rana, M. S., Kleist, A. B., Flerlage, T., Feith, D. J., . . . Mullighan, C. G. (2022). CCL22 mutations drive natural killer cell lymphoproliferative disease by deregulating microenvironmental crosstalk. NATURE GENETICS, 54(5), 637-+. doi:10.1038/s41588-022-01059-2

Ung, J., Tan, S. -F., Fox, T. E., Shaw, J. J. P., Vass, L. R., Costa-Pinheiro, P., . . . Loughran, T. P. (2022). Harnessing the power of sphingolipids: Prospects for acute myeloid leukemia. BLOOD REVIEWS, 55. doi:10.1016/j.blre.2022.100950

Huuhtanen, J., Bhattacharya, D., Lonnberg, T., Kankainen, M., Kerr, C., Theodoropoulos, J., . . . Mustjoki, S. (2022). Single-cell characterization of leukemic and non-leukemic immune repertoires in CD8⁺ T-cell large granular lymphocytic leukemia. NATURE COMMUNICATIONS, 13(1). doi:10.1038/s41467-022-29173-z

Cheon, H., Xing, J. C., Moosic, K. B., Ung, J., Chan, V. W., Chung, D. S., . . . Loughran Jr, T. P. (2022). Genomic landscape of TCRαβ and TCRγδ T-large granular lymphocyte leukemia. BLOOD, 139(20), 3058-3072. doi:10.1182/blood.2021013164

Fisher-Wellman, K. H., Hagen, J. T., Kassai, M., Kao, L. -P., Nelson, M. A. M., McLaughlin, K. L., . . . Cabot, M. C. (2022). Alterations in sphingolipid composition and mitochondrial bioenergetics represent synergistic therapeutic vulnerabilities linked to multidrug resistance in leukemia. FASEB JOURNAL, 36(1). doi:10.1096/fj.202101194RRR

Assmann, J. L. J. C., Leon, L. G., Stavast, C. J., van den Bogaerdt, S. E., Schilperoord-Vermeulen, J., Sandberg, Y., . . . Langerak, A. W. (2022). miR-181a is a novel player in the STAT3-mediated survival network of TCRαβ+CD8+T large granular lymphocyte leukemia. LEUKEMIA, 36(4), 983-993. doi:10.1038/s41375-021-01480-2

Golla, U., Ehudin, M. A., Annageldiyev, C., Zeng, Z., Bastihalli Tukaramrao, D., Tarren, A., . . . Sharma, A. (2021). DJ4 Targets the Rho-Associated Protein Kinase Pathway and Attenuates Disease Progression in Preclinical Murine Models of Acute Myeloid Leukemia. CANCERS, 13(19). doi:10.3390/cancers13194889

Olson, T. L., Cheon, H., Xing, J. C., Olson, K. C., Paila, U., Hamele, C. E., . . . Loughran, T. P. J. (2021). Frequent somatic TET2 mutations in chronic NK-LGL leukemia with distinct patterns of cytopenias. BLOOD, 138(8), 662-673. doi:10.1182/blood.2020005831

Fox, J., He, M., Loughran, T., Synold, T., & Uthamanthil, R. (2020). Submitting Successful Cancer Center Support Grants (P30) from the Core Perspective.. Journal of biomolecular techniques : JBT, 31(Suppl), S41.

Cherel, B., Humbert, M., LeBlanc, F. R., Zambello, R., Hamidou, M., Lifermann, F., . . . Lamy, T. (2020). Large Granular Lymphocyte Leukemia and Precapillary Pulmonary Hypertension. CHEST, 158(6), 2602-2609. doi:10.1016/j.chest.2020.07.094

Olson, K. C., Moosic, K. B., Jones, M. K., Larkin, P. M. K., Olson, T. L., Toro, M. F., . . . Loughran, T. P. J. (2020). Large granular lymphocyte leukemia serum and corresponding hematological parameters reveal unique cytokine and sphingolipid biomarkers and associations with STAT3 mutations. CANCER MEDICINE, 9(18), 6533-6549. doi:10.1002/cam4.3246

Mittal, N., Loughran, T. J., & Rivers, A. (2020). T-cell large granular lymphocytic leukemia successfully treated with oral cyclosporine in a child: Case report and review of literature. PEDIATRIC BLOOD & CANCER, 67(12). doi:10.1002/pbc.28487

Annageldiyev, C., Tan, S. -F., Thakur, S., Dhanyamraju, P. K., Ramisetti, S. R., Bhadauria, P., . . . Sharma, A. (2020). The PI3K/AKT Pathway Inhibitor ISC-4 Induces Apoptosis and Inhibits Growth of Leukemia in Preclinical Models of Acute Myeloid Leukemia. FRONTIERS IN ONCOLOGY, 10. doi:10.3389/fonc.2020.00393

LeBlanc, F. R., Pearson, J. M., Tan, S. -F., Cheon, H., Xing, J. C., Dunton, W., . . . Loughran, T. P. J. (2020). Sphingosine kinase-2 is overexpressed in large granular lymphocyte leukaemia and promotes survival through Mcl-1. BRITISH JOURNAL OF HAEMATOLOGY, 190(3), 405-417. doi:10.1111/bjh.16530

Cheon, H., Dziewulska, K. H., Moosic, K. B., Olson, K. C., Gru, A. A., Feith, D. J., & Loughran, T. P. J. (2020). Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 15(2), 103-112. doi:10.1007/s11899-020-00565-6

Wang, T. T., Yang, J., Dighe, S., Schmachtenberg, M. W., Leigh, N. T., Farber, E., . . . Olson, T. L. (2020). Whole Genome Sequencing of Spontaneously Occurring Rat Natural Killer Large Granular Lymphocyte Leukemia Identifies JAK1 Somatic Activating Mutation. CANCERS, 12(1). doi:10.3390/cancers12010126

Pearson, J. M., Tan, S. -F., Sharma, A., Annageldiyev, C., Fox, T. E., Abad, J. L., . . . Loughran, T. P. (2020). Ceramide Analogue SACLAC Modulates Sphingolipid Levels and MCL-1 Splicing to Induce Apoptosis in Acute Myeloid Leukemia. MOLECULAR CANCER RESEARCH, 18(3), 352-363. doi:10.1158/1541-7786.MCR-19-0619

Nyland, S. B., Feith, D. J., Poss, M., Olson, T. L., Krissinger, D. J., Poiesz, B. J., . . . Loughran, T. P. (2020). Retroviral sero-reactivity in LGL leukaemia patients and family members. BRITISH JOURNAL OF HAEMATOLOGY, 188(4), 522-527. doi:10.1111/bjh.16223

Barth, B. M., Wang, W., Toran, P. T., Fox, T. E., Annageldiyev, C., Ondrasik, R. M., . . . Claxton, D. F. (2019). Sphingolipid metabolism determines the therapeutic efficacy of nanoliposomal ceramide in acute myeloid leukemia. BLOOD ADVANCES, 3(17), 2598-2603. doi:10.1182/bloodadvances.2018021295

Annageldiyev, C., Gowda, K., Patel, T., Bhattacharya, P., Tan, S. -F., Iyer, S., . . . Sharma, A. (2020). The novel Isatin analog KS99 targets stemness markers in acute myeloid leukemia. HAEMATOLOGICA, 105(3), 687-696. doi:10.3324/haematol.2018.212886

Morad, S. A. F., MacDougall, M. R., Abdelmageed, N., Kao, L. -P., Feith, D. J., Tan, S. -F., . . . Cabot, M. C. (2019). Pivotal role of mitophagy in response of acute myelogenous leukemia to a ceramide-tamoxifen-containing drug regimen. EXPERIMENTAL CELL RESEARCH, 381(2), 256-264. doi:10.1016/j.yexcr.2019.05.021

Lamy, T., & Loughran, T. P. (2019). Large granular lymphocytic and other rare lymphoid leukemias Preface. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 32(3), 193-195. doi:10.1016/j.beha.2019.09.001

Kao, L. -P., Morad, S. A. F., Davis, T. S., MacDougall, M. R., Kassai, M., Abdelmageed, N., . . . Cabot, M. C. (2019). Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells. JOURNAL OF LIPID RESEARCH, 60(9), 1590-1602. doi:10.1194/jlr.RA119000251

Moosic, K. B., Paila, U., Olson, K. C., Dziewulska, K., Wang, T. T., Xing, J. C., . . . Olson, T. L. (2019). Genomics of LGL leukemia and select other rare leukemia/lymphomas. BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 32(3), 196-206. doi:10.1016/j.beha.2019.06.003

Li, W., Yang, L., Harris, R. S., Lin, L., Olson, T. L., Hamele, C. E., . . . Poss, M. (2019). Retrovirus insertion site analysis of LGL leukemia patient genomes. BMC MEDICAL GENOMICS, 12. doi:10.1186/s12920-019-0549-9

Tan, S. -F., Dunton, W., Liu, X., Fox, T. E., Morad, S. A. F., Desai, D., . . . Loughran, T. P. (2019). Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-B-dependent P-glycoprotein upregulation. JOURNAL OF LIPID RESEARCH, 60(6), 1078-1086. doi:10.1194/jlr.M091876

Olson, K. C., Larkin, P. M. K., Signorelli, R., Hamele, C. E., Olson, T. L., Conaway, M. R., . . . Loughran, T. P. J. (2018). Vitamin D pathway activation selectively deactivates signal transducer and activator of transcription (STAT) proteins and inflammatory cytokine production in natural killer leukemic large granular lymphocytes. CYTOKINE, 111, 551-562. doi:10.1016/j.cyto.2018.09.016

Wang, T. T., Yang, J., Zhang, Y., Zhang, M., Dubois, S., Conlon, K. C., . . . Loughran, T. P. J. (2019). IL-2 and IL-15 blockade by BNZ-1, an inhibitor of selective γ-chain cytokines, decreases leukemic T-cell viability. LEUKEMIA, 33(5), 1243-1255. doi:10.1038/s41375-018-0290-y

Olson, T. L., & Loughran, T. P. J. (2018). Restoring the Long Noncoding RNA MEG3 Indicates a Potential Role for JAK-STAT Signaling in Chronic Myeloid Leukemia. EBIOMEDICINE, 35, 24. doi:10.1016/j.ebiom.2018.08.019

Yang, J., LeBlanc, F. R., Dighe, S. A., Hamele, C. E., Olson, T. L., Feith, D. J., & Loughran, T. P. J. (2018). TRAIL mediates and sustains constitutive NF-κB activation in LGL leukemia. BLOOD, 131(25), 2803-2815. doi:10.1182/blood-2017-09-808816

Dufva, O., Kankainen, M., Kelkka, T., Sekiguchi, N., Awad, S. A., Eldfors, S., . . . Mustjoki, S. (2018). Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target. NATURE COMMUNICATIONS, 9. doi:10.1038/s41467-018-03987-2

Kulling, P. M., Olson, K. C., Hamele, C. E., Toro, M. F., Tan, S. -F., Feith, D. J., & Loughran, T. P. J. (2018). Dysregulation of the IFN-γ-STAT1 signaling pathway in a cell line model of large granular lymphocyte leukemia. PLOS ONE, 13(2). doi:10.1371/journal.pone.0193429

Savola, P., Bruck, O., Olson, T., Kelkka, T., Kauppi, M. J., Kovanen, P. E., . . . Mustjoki, S. (2018). Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia. HAEMATOLOGICA, 103(2), 304-312. doi:10.3324/haematol.2017.175729

Kulling, P. M., Olson, K. C., Olson, T. L., Hamele, C. E., Carter, K. N., Feith, D. J., & Loughran, T. P. J. (2018). Calcitriol-mediated reduction in IFN-γ output in T cell large granular lymphocytic leukemia requires vitamin D receptor upregulation. JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 177, 140-148. doi:10.1016/j.jsbmb.2017.07.009

Tan, S. -F., Pearson, J. M., Feith, D. J., & Loughran, T. P. J. (2017). The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia. EXPERT OPINION ON THERAPEUTIC TARGETS, 21(6), 583-590. doi:10.1080/14728222.2017.1322065

Morad, S. A. F., Davis, T. S., MacDougall, M. R., Tan, S. -F., Feith, D. J., Desai, D. H., . . . Cabot, M. G. (2017). Role of P-glycoprotein inhibitors in ceramide-based therapeutics for treatment of cancer. BIOCHEMICAL PHARMACOLOGY, 130, 21-33. doi:10.1016/j.bcp.2017.02.002

Gazitt, T., & Loughran, T. P. J. (2017). Chronic neutropenia in LGL leukemia and rheumatoid arthritis. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 181-186. doi:10.1182/asheducation-2017.1.181

Hengst, J. A., Dick, T. E., Sharma, A., Doi, K., Hegde, S., Tan, S. -F., . . . Yun, J. K. (2017). SKI-178: A Multitargeted Inhibitor of Sphingosine Kinase and Microtubule Dynamics Demonstrating Therapeutic Efficacy in Acute Myeloid Leukemia Models.. Cancer translational medicine, 3(4), 109-121. doi:10.4103/ctm.ctm_7_17

Salzberg, A. C., Harris-Becker, A., Popova, E. Y., Keasey, N., Loughran, T. P., Claxton, D. F., & Grigoryev, S. A. (2017). Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability. PLOS ONE, 12(3). doi:10.1371/journal.pone.0173723

Salzberg, A. C., Harris-Becker, A., Popova, E. Y., Keasey, N., Loughran, T. P., Claxton, D. F., & Grigoryev, S. A. (2017). Genome-wide mapping of histone H3K9me2 in acute myeloid leukemia reveals large chromosomal domains associated with massive gene silencing and sites of genome instability.. PloS one, 12(3), e0173723. doi:10.1371/journal.pone.0173723

Lamy, T., Moignet, A., & Loughran, T. P. J. (2017). LGL leukemia: from pathogenesis to treatment. BLOOD, 129(9), 1082-1094. doi:10.1182/blood-2016-08-692590

Olson, K. C., Kulling, P. M., Olson, T. L., Tan, S. -F., Rainbow, R. J., Feith, D. J., & Loughran, T. P. J. (2017). Vitamin D decreases STAT phosphorylation and inflammatory cytokine output in T-LGL leukemia. CANCER BIOLOGY & THERAPY, 18(5), 290-303. doi:10.1080/15384047.2016.1235669

Kulling, P. M., Olson, K. C., Olson, T. L., Feith, D. J., & Loughran, T. P. J. (2017). Vitamin D in hematological disorders and malignancies. EUROPEAN JOURNAL OF HAEMATOLOGY, 98(3), 187-197. doi:10.1111/ejh.12818

Gazitt, T., Lood, C., Sun, X., Feith, D., Ledbetter, J., Starkebaum, G., . . . Elkon, K. B. (2016). Cell-Mediated Neutrophil Lysis-a Mechanism Promoting Hypercitrullination in Rheumatoid Arthritis?. ARTHRITIS & RHEUMATOLOGY, 68.

Tan, S. -F., Liu, X., Fox, T. E., Barth, B. M., Sharma, A., Turner, S. D., . . . Loughran, T. P. J. (2016). Acid ceramidase is upregulated in AML and represents a novel therapeutic target. ONCOTARGET, 7(50), 83208-83222. doi:10.18632/oncotarget.13079

Andersson, E. I., Tanahashi, T., Sekiguchi, N., Gasparini, V. R., Bortoluzzi, S., Kawakami, T., . . . Ishida, F. (2016). High incidence of activating STAT5B mutations in CD4-positive T-cell large granular lymphocyte leukemia. BLOOD, 128(20), 2465-2468. doi:10.1182/blood-2016-06-724856

Sang, W., Sun, C., Zhang, C., Zhang, D., Wang, Y., Xu, L., . . . Xu, K. (2016). MicroRNA-150 negatively regulates the function of CD4⁺ T cells through AKT3/Bim signaling pathway. CELLULAR IMMUNOLOGY, 306, 35-40. doi:10.1016/j.cellimm.2016.05.007

Morad, S. A. F., Ryan, T. E., Neufer, P. D., Zeczycki, T. N., Davis, T. S., MacDougall, M. R., . . . Cabot, M. C. (2016). Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia. JOURNAL OF LIPID RESEARCH, 57(7), 1231-1242. doi:10.1194/jlr.M067389

Sang, W., Wang, Y., Zhang, C., Yan, D., Niu, M., Yang, C., . . . Xu, K. (2016). Fludarabine, idarubicin, and cytarabine regimen together with TKI followed by haploidentical hematopoietic stem cell transplantation, a success for relapsed Ph+ acute lymphoblastic leukemia. CLINICAL CASE REPORTS, 4(4), 390-395. doi:10.1002/ccr3.438

Epner, E. M., Saroya, B. S., Hasanali, Z. S., & Loughran, T. P. J. (2016). Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach. EXPERIMENTAL HEMATOLOGY, 44(3), 157-160. doi:10.1016/j.exphem.2015.12.011

Andersson, E., Kuusanmaki, H., Bortoluzzi, S., Lagstrom, S., Parsons, A., Rajala, H., . . . Mustjoki, S. (2016). Activating somatic mutations outside the SH2-domain of STAT3 in LGL leukemia. LEUKEMIA, 30(5), 1204-1208. doi:10.1038/leu.2015.263

Sang, W., Wang, Y., Zhang, C., Zhang, D., Sun, C., Niu, M., . . . Xu, K. (2016). MiR-150 impairs inflammatory cytokine production by targeting ARRB-2 after blocking CD28/B7 costimulatory pathway. IMMUNOLOGY LETTERS, 172, 1-10. doi:10.1016/j.imlet.2015.11.001

Morad, S. A. F., Davis, T. S., Kester, M., Loughran, T. P. J., & Cabot, M. C. (2015). Dynamics of ceramide generation and metabolism in response to fenretinide - Diversity within and among leukemia. LEUKEMIA RESEARCH, 39(10), 1071-1078. doi:10.1016/j.leukres.2015.06.009

Steinway, S. N., Biggs, M. B., Loughran, T. P. J., Papin, J. A., & Albert, R. (2015). Inference of Network Dynamics and Metabolic Interactions in the Gut Microbiome. PLOS COMPUTATIONAL BIOLOGY, 11(6). doi:10.1371/journal.pcbi.1004338

Morad, S. A. F., Tan, S. -F., Feith, D. J., Kester, M., Claxton, D. F., Loughran, T. P. J., . . . Cabot, M. C. (2015). Modification of sphingolipid metabolism by tamoxifen and N-desmethyltamoxifen in acute myelogenous leukemia-Impact on enzyme activity and response to cytotoxics. BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS, 1851(7), 919-928. doi:10.1016/j.bbalip.2015.03.001

Steinway, S. N., Zanudo, J. G. T., Michel, P. J., Feith, D. J., Loughran, T. P., & Albert, R. (2015). Combinatorial interventions inhibit TGFβ-driven epithelial-to-mesenchymal transition and support hybrid cellular phenotypes. NPJ SYSTEMS BIOLOGY AND APPLICATIONS, 1. doi:10.1038/npjsba.2015.14

Perzova, R., Graziano, E., Sanghi, S., Welch, C., Benz, P., Abbott, L., . . . Poiesz, B. J. (2015). Increased Seroreactivity to Human T Cell Lymphoma/Leukemia Virus-Related Endogenous Sequence-1 Gag Peptides in Patients with Human T Cell Lymphoma/Leukemia Virus Myelopathy. AIDS RESEARCH AND HUMAN RETROVIRUSES, 31(2), 242-249. doi:10.1089/aid.2014.0171

Ren, T., Takahashi, Y., Liu, X., Loughran, T. P., Sun, S. -C., Wang, H. -G., & Cheng, H. (2015). HTLV-1 Tax deregulates autophagy by recruiting autophagic molecules into lipid raft microdomains. ONCOGENE, 34(3), 373-384. doi:10.1038/onc.2013.552

LeBlanc, F. R., Liu, X., Hengst, J., Fox, T., Calvert, V., Petricoin, E. F. I. I. I., . . . Loughran, T. P. J. (2015). Sphingosine kinase inhibitors decrease viability and induce cell death in natural killer-large granular lymphocyte leukemia. CANCER BIOLOGY & THERAPY, 16(12), 1830-1840. doi:10.1080/15384047.2015.1078949

LeBlanc, F. R., & Loughran, T. P. J. (2015). Large granular lymphocyte leukemia: clinical background, molecular pathogenesis and treatment. EXPERT OPINION ON ORPHAN DRUGS, 3(8), 859-867. doi:10.1517/21678707.2015.1062362

Sang, W., Zhang, C., Zhang, D., Wang, Y., Sun, C., Niu, M., . . . Xu, K. (2015). MicroRNA-181a, a potential diagnosis marker, alleviates acute graft versus host disease by regulating IFN- production. AMERICAN JOURNAL OF HEMATOLOGY, 90(11), 998-1007. doi:10.1002/ajh.24136

Hasanali, Z. S., Saroya, B. S., Stuart, A., Shimko, S., Evans, J., Shah, M. V., . . . Epner, E. M. (2015). Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. SCIENCE TRANSLATIONAL MEDICINE, 7(293). doi:10.1126/scitranslmed.aaa5079

Ratan, A., Olson, T. L., Loughran, T. P. J., & Miller, W. (2015). Identification of indels in next-generation sequencing data. BMC BIOINFORMATICS, 16. doi:10.1186/s12859-015-0483-6

Yan, Y., Olson, T. L., Nyland, S. B., Feith, D. J., & Loughran, T. P. (2015). Emergence of a STAT3 mutated NK clone in LGL leukemia.. Leukemia research reports, 4(1), 4-7. doi:10.1016/j.lrr.2014.12.001

Dick, T. E., Hengst, J. A., Fox, T. E., Colledge, A. L., Kale, V. P., Sung, S. -S., . . . Yun, J. K. (2015). The Apoptotic Mechanism of Action of the Sphingosine Kinase 1 Selective Inhibitor SKI-178 in Human Acute Myeloid Leukemia Cell Lines. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 352(3), 494-508. doi:10.1124/jpet.114.219659

Rajala, H. L. M., Olson, T., Clemente, M. J., Lagstrom, S., Ellonen, P., Lundan, T., . . . Mustjoki, S. (2015). The analysis of clonal diversity and therapy responses using STAT3 mutations as a molecular marker in large granular lymphocytic leukemia. HAEMATOLOGICA, 100(1), 91-99. doi:10.3324/haematol.2014.113142

Murphy, P. W., Brett, L. K., Verla-Tebit, E., Macik, B. G., & Loughran, T. P. J. (2015). Acquired inhibitors to factor VIII and fibrinogen in the setting of T-cell large granular lymphocyte leukemia: a case report and review of the literature. BLOOD COAGULATION & FIBRINOLYSIS, 26(2), 211-213. doi:10.1097/MBC.0000000000000209

Sun, X., Hasanali, Z. S., Chen, A., Zhang, D., Liu, X., Wang, H. -G., . . . Xu, K. (2015). Suberoylanilide hydroxamic acid (SAHA) and cladribine synergistically induce apoptosis in NK-LGL leukaemia. BRITISH JOURNAL OF HAEMATOLOGY, 168(3), 371-383. doi:10.1111/bjh.13143

Cheng, J., Talamo, G., Malysz, J., Ochmann, M., Lamy, T., & Loughran, T. P. (2014). Report of 6 cases of large granular lymphocytic leukemia and plasma cell dyscrasia.. Clinical lymphoma, myeloma & leukemia, 14(5), e169-e172. doi:10.1016/j.clml.2014.04.001

Loughran, T. P. J., Zickl, L., Olson, T. L., Wang, V., Zhang, D., Rajala, H. L. M., . . . Tallman, M. S. (2015). Immunosuppressive therapy of LGL leukemia: prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). LEUKEMIA, 29(4), 886-894. doi:10.1038/leu.2014.298

Barth, B. M., Keasey, N. R., Wang, X., Shanmugavelandy, S. S., Rampal, R., Hricik, T., . . . Claxton, D. F. (2014). Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation.. Journal of leukemia (Los Angeles, Calif.), 2(3), 146. doi:10.4172/2329-6917.1000146

Steinway, S. N., LeBlanc, F., & Loughran, T. P. J. (2014). The pathogenesis and treatment of large granular lymphocyte leukemia. BLOOD REVIEWS, 28(3), 87-94. doi:10.1016/j.blre.2014.02.001

Moignet, A., Hasanali, Z., Zambello, R., Pavan, L., Bareau, B., Tournilhac, O., . . . Lamy, T. (2014). Cyclophosphamide as a first-line therapy in LGL leukemia. LEUKEMIA, 28(5), 1134-1136. doi:10.1038/leu.2013.359

Doi, K., Liu, Q., Gowda, K., Barth, B. M., Claxton, D., Amin, S., . . . Wang, H. -G. (2014). Maritoclax induces apoptosis in acute myeloid leukemia cells with elevated Mcl-1 expression. CANCER BIOLOGY & THERAPY, 15(8), 1077-1086. doi:10.4161/cbt.29186

Doi, K., Gowda, K., Liu, Q., Lin, J. -M., Sung, S. -S., Dower, C., . . . Wang, H. -G. (2014). Pyoluteorin derivatives induce Mcl-1 degradation and apoptosis in hematological cancer cells. CANCER BIOLOGY & THERAPY, 15(12), 1688-1699. doi:10.4161/15384047.2014.972799

Zhang, L., Ramchandren, R., Papenhausen, P., Loughran, T. P., & Sokol, L. (2014). Transformed aggressive γδ-variant T-cell large granular lymphocytic leukemia with acquired copy neutral loss of heterozygosity at 17q11.2q25.3 and additional aberrations. EUROPEAN JOURNAL OF HAEMATOLOGY, 93(3), 260-264. doi:10.1111/ejh.12313

Hasanali, Z. S., Epner, E. M., Feith, D. J., Loughran, T. P. J., & Sample, C. E. (2014). Vorinostat Downregulates CD30 and Decreases Brentuximab Vedotin Efficacy in Human Lymphocytes. MOLECULAR CANCER THERAPEUTICS, 13(12), 2784-2792. doi:10.1158/1535-7163.MCT-14-0593

Poullot, E., Zambello, R., Leblanc, F., Bareau, B., De March, E., Roussel, M., . . . Lamy, T. (2014). Chronic natural killer lymphoproliferative disorders: characteristics of an international cohort of 70 patients. ANNALS OF ONCOLOGY, 25(10), 2030-2035. doi:10.1093/annonc/mdu369

Rajala, H. L. M., Porkka, K., Maciejewski, J. P., Loughran, T. P. J., & Mustjoki, S. (2014). Uncovering the pathogenesis of large granular lymphocytic leukemia-novel STAT3 and STAT5b mutations. ANNALS OF MEDICINE, 46(3), 114-122. doi:10.3109/07853890.2014.882105

Steinway, S. N., Zanudo, J. G. T., Ding, W., Rountree, C. B., Feith, D. J., Loughran, T. P. J., & Albert, R. (2014). Network Modeling of TGFβ Signaling in Hepatocellular Carcinoma Epithelial-to-Mesenchymal Transition Reveals Joint Sonic Hedgehog and Wnt Pathway Activation. CANCER RESEARCH, 74(21), 5963-5977. doi:10.1158/0008-5472.CAN-14-0225

Ren, T., Yang, J., Broeg, K., Liu, X., Loughran, T. P. J., & Cheng, H. (2013). Developing an in vitro model of T cell type of large granular lymphocyte leukemia. LEUKEMIA RESEARCH, 37(12), 1737-1743. doi:10.1016/j.leukres.2013.10.002

Steinway, S. N., & Loughran, T. P. (2013). Targeting IL-15 in large granular lymphocyte leukemia. EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 9(5), 405-408. doi:10.1586/ECI.13.28

Ren, T., Dong, W., Takahashi, Y., Loughran, T. P., Sun, S. -C., Wang, H. -G., & Cheng, H. (2013). HTLV-1 Tax deregulates autophagy in promoting T-cell survival and proliferation.. CANCER RESEARCH, 73(8). doi:10.1158/1538-7445.AM2013-1067

Mailloux, A., Zhang, L., Moscinski, L., Bennett, J., Yang, L., Yoder, S., . . . Epling-Burnette, P. (2013). Pathophysiology of cytopenias in an autoimmune lymphoproliferative disease linked to bone marrow fibrosis. JOURNAL OF IMMUNOLOGY, 190.

Perzova, R., Graziano, E., Sanghi, S., Welch, C., Benz, P., Abbott, L., . . . Poiesz, B. J. (2013). Increased seroreactivity to HERV-K10 peptides in patients with HTLV myelopathy. VIROLOGY JOURNAL, 10. doi:10.1186/1743-422X-10-360

Yang, L., Mailloux, A., Rollison, D. E., Painter, J. S., Maciejewski, J., Paquette, R. L., . . . Epling-Burnette, P. K. (2013). Naive T-cells in myelodysplastic syndrome display intrinsic human telomerase reverse transcriptase (hTERT) deficiency. LEUKEMIA, 27(4), 897-906. doi:10.1038/leu.2012.300

Watters, R. J., & Loughran, T. P. J. (2013). Diagnosing large granular lymphocyte leukemia is bloody difficult. LEUKEMIA & LYMPHOMA, 54(2), 438-439. doi:10.3109/10428194.2012.728290

LeBlanc, F. R., Hasanali, Z. S., & Loughran, T. P. J. (2013). Does IL-15 have a causative role in large granular lymphocyte leukemia?. IMMUNOTHERAPY, 5(3), 231-234. doi:10.2217/IMT.13.7

Shah, M. V., Barochia, A., & Loughran, T. P. J. (2013). Impact of Genetic Targets on Cancer Therapy in Acute Myelogenous Leukemia. IMPACT OF GENETIC TARGETS ON CANCER THERAPY, 779, 405-437. doi:10.1007/978-1-4614-6176-0_19

Rajala, H. L. M., Eldfors, S., Kuusanmaki, H., van Adrichem, A. J., Olson, T., Lagstrom, S., . . . Mustjoki, S. (2013). Discovery of somatic STAT5b mutations in large granular lymphocytic leukemia. BLOOD, 121(22), 4541-4550. doi:10.1182/blood-2012-12-474577

Aumiller, B. B., Parrott, R., Lengerich, E. J., Dominic, O., Camacho, F., Lehman, E., . . . Loughran, T. P. (2013). Responses to a Theoretically Adapted Clinical Trial Education Session: Faith-Based Sites Versus Rural Work Site Dissemination. JOURNAL OF CANCER EDUCATION, 28(4), 698-708. doi:10.1007/s13187-013-0517-6

Jerez, A., Clemente, M. J., Makishima, H., Rajala, H., Gomez-Segui, I., Olson, T., . . . Maciejewski, J. P. (2013). STAT3 mutations indicate the presence of subclinical T-cell clones in a subset of aplastic anemia and myelodysplastic syndrome patients. BLOOD, 122(14), 2453-2459. doi:10.1182/blood-2013-04-494930

Mailloux, A. W., Zhang, L., Moscinski, L., Bennett, J. M., Yang, L., Yoder, S. J., . . . Epling-Burnette, P. K. (2013). Fibrosis and Subsequent Cytopenias Are Associated with Basic Fibroblast Growth Factor-Deficient Pluripotent Mesenchymal Stromal Cells in Large Granular Lymphocyte Leukemia. JOURNAL OF IMMUNOLOGY, 191(7), 3578-3593. doi:10.4049/jimmunol.1203424

Andersson, E. I., Rajala, H. L. M., Eldfors, S., Ellonen, P., Olson, T., Jerez, A., . . . Mustjoki, S. (2013). Novel somatic mutations in large granular lymphocytic leukemia affecting the STAT-pathway and T-cell activation. BLOOD CANCER JOURNAL, 3. doi:10.1038/bcj.2013.65

Bedoya-Reina, O. C., Ratan, A., Burhans, R., Kim, H. L., Giardine, B., Riemer, C., . . . Miller, W. (2013). Galaxy tools to study genome diversity. GIGASCIENCE, 2. doi:10.1186/2047-217X-2-17

Ryland, L. K., Doshi, U. A., Shanmugavelandy, S. S., Fox, T. E., Aliaga, C., Broeg, K., . . . Kester, M. (2013). C6-Ceramide Nanoliposomes Target the Warburg Effect in Chronic Lymphocytic Leukemia. PLOS ONE, 8(12). doi:10.1371/journal.pone.0084648

Watters, R. J., Fox, T. E., Tan, S. -F., Shanmugavelandy, S., Choby, J. E., Broeg, K., . . . Liu, X. (2013). Targeting glucosylceramide synthase synergizes with C₆-ceramide nanoliposomes to induce apoptosis in natural killer cell leukemia. LEUKEMIA & LYMPHOMA, 54(6), 1288-1296. doi:10.3109/10428194.2012.752485

LeBlanc, F., Zhang, D., Liu, X., & Loughran, T. P. J. (2012). Large granular lymphocyte leukemia: from dysregulated pathways to therapeutic targets. FUTURE ONCOLOGY, 8(7), 787-801. doi:10.2217/FON.12.75

Koskela, H. L. M., Eldfors, S., Ellonen, P., van Adrichem, A. J., Kuusanmaki, H., Andersson, E. I., . . . Mustjoki, S. (2012). Somatic STAT3 Mutations in Large Granular Lymphocytic Leukemia. NEW ENGLAND JOURNAL OF MEDICINE, 366(20), 1905-1913. doi:10.1056/NEJMoa1114885

Nyland, S. B., Krissinger, D. J., Clemente, M. J., Irby, R. B., Baab, K. T., Jarbadan, N. R., . . . Loughran, T. P. J. (2012). Seroreactivity to LGL leukemia-specific epitopes in aplastic anemia, myelodysplastic syndrome and paroxysmal nocturnal hemoglobinuria: Results of a bone marrow failure consortium study. LEUKEMIA RESEARCH, 36(5), 581-587. doi:10.1016/j.leukres.2012.02.001

Andersson, E., Eldfors, S., Koskela, H., Ellonen, P., Kallioniemi, O., Porkka, K., . . . Mustjoki, S. (2012). Exome Sequencing of T-LGL Leukemia Patient Revealed ANGPT2 as a Possible Mutational Target. EUROPEAN JOURNAL OF CANCER, 48, S198. doi:10.1016/S0959-8049(12)71458-2

Ren, T., Dong, W., Takahashi, Y., Xiang, D., Yuan, Y., Liu, X., . . . Cheng, H. (2012). Oncogenic properties of tax protein from human T cell leukemia virus type 2. CANCER RESEARCH, 72. doi:10.1158/1538-7445.AM2012-LB-66

Mailloux, A. W., Sugimori, C., Komrokji, R. S., Maciejewski, J. P., Sekeres, M. A., Paquette, R., . . . Epling-Burnette, P. K. (2012). Expansion of effector regulatory T-cells represents a novel and independent prognostic factor marking escape from immune surveillance in Myleodysplastic Syndrome. CANCER RESEARCH, 72. doi:10.1158/1538-7445.AM2012-5417

Hasanali, Z., Sharma, K., Shimko, S., Stuart, A., Liu, X., Epner, E. E., & Loughran, T. P. (2012). Epigenetically induced expression of CD30 in T-PLL: A rationale for the use of brentuximab vedotin. JOURNAL OF CLINICAL ONCOLOGY, 30(15).

Doi, K., Li, R., Sung, S. -S., Wu, H., Liu, Y., Manieri, W., . . . Wang, H. -G. (2012). Discovery of Marinopyrrole A (Maritoclax) as a Selective Mcl-1 Antagonist that Overcomes ABT-737 Resistance by Binding to and Targeting Mcl-1 for Proteasomal Degradation. JOURNAL OF BIOLOGICAL CHEMISTRY, 287(13), 10224-10235. doi:10.1074/jbc.M111.334532

Jerez, A., Clemente, M. J., Makishima, H., Koskela, H., LeBlanc, F., Ng, K. P., . . . Maciejewski, J. P. (2012). STAT3 mutations unify the pathogenesis of chronic lymphoproliferative disorders of NK cells and T-cell large granular lymphocyte leukemia. BLOOD, 120(15), 3048-3057. doi:10.1182/blood-2012-06-435297

Mailloux, A. W., Sugimori, C., Komrokji, R. S., Yang, L., Maciejewski, J. P., Sekeres, M. A., . . . Epling-Burnette, P. K. (2012). Expansion of Effector Memory Regulatory T Cells Represents a Novel Prognostic Factor in Lower Risk Myelodysplastic Syndrome. JOURNAL OF IMMUNOLOGY, 189(6), 3198-3208. doi:10.4049/jimmunol.1200602

Ren, T., Dong, W., Takahashi, Y., Xiang, D., Yuan, Y., Liu, X., . . . Cheng, H. (2012). HTLV-2 Tax Immortalizes Human CD4⁺ Memory T Lymphocytes by Oncogenic Activation and Dysregulation of Autophagy. JOURNAL OF BIOLOGICAL CHEMISTRY, 287(41), 34683-34693. doi:10.1074/jbc.M112.377143

Zhang, D., & Loughran, T. P. J. (2012). Large granular lymphocytic leukemia: molecular pathogenesis, clinical manifestations, and treatment. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 652-659. doi:10.1182/asheducation-2012.1.652

Waters, R. J., Kester, M., Tran, M. A., Loughran, T. P. J., & Liu, X. (2012). DEVELOPMENT AND USE OF CERAMIDE NANOLIPOSOMES IN CANCER. NANOMEDICINE: CANCER, DIABETES, AND CARDIOVASCULAR, CENTRAL NERVOUS SYSTEM, PULMONARY AND INFLAMMATORY DISEASES, 508, 89-108. doi:10.1016/B978-0-12-391860-4.00005-7

Watters, R. J., Wang, H. -G., Sung, S. -S., Loughran, T. P. J., & Liu, X. (2011). Targeting Sphingosine-1-Phosphate Receptors in Cancer. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 11(9), 810-817.

Loughran, T. P., & Wang, H. -G. (2011). Editorial [hot topic: Therapeutic targeting of the sphingolipid "biostat" in hematologic malignancies (guest editors: Thomas P. Loughran and Hong-Gang Wang)].. Anti-cancer agents in medicinal chemistry, 11(9), 780-781. doi:10.2174/187152011797655113

El-Bayoumy, K., Das, A., Russell, S., Wolfe, S., Jordan, R., Renganathan, K., . . . Somiari, R. (2012). The effect of selenium enrichment on baker's yeast proteome. JOURNAL OF PROTEOMICS, 75(3), 1018-1030. doi:10.1016/j.jprot.2011.10.013

Bai, F., Villagra, A. V., Zou, J., Painter, J. S., Connolly, K., Blaskovich, M. A., . . . Epling-Burnette, P. (2012). Tipifarnib-mediated suppression of T-bet-dependent signaling pathways. CANCER IMMUNOLOGY IMMUNOTHERAPY, 61(4), 523-533. doi:10.1007/s00262-011-1109-0

Watters, R. J., Liu, X., & Loughran, T. P. J. (2011). T-cell and natural killer-cell large granular lymphocyte leukemia neoplasias. LEUKEMIA & LYMPHOMA, 52(12), 2217-2225. doi:10.3109/10428194.2011.593276

Liu, X., & Loughran, T. P. J. (2011). The spectrum of large granular lymphocyte leukemia and Felty's syndrome. CURRENT OPINION IN HEMATOLOGY, 18(4), 254-259. doi:10.1097/MOH.0b013e32834760fb

Zhang, R., & Loughran, T. P. J. (2011). Off-target effects of tyrosine kinase inhibitors: Beauty or the Beast?. LEUKEMIA & LYMPHOMA, 52(4), 556-557. doi:10.3109/10428194.2011.560694

Ryland, L. K., Fox, T. E., Liu, X., Loughran, T. P., & Kester, M. (2011). Dysregulation of sphingolipid metabolism in cancer. CANCER BIOLOGY & THERAPY, 11(2), 138-149. doi:10.4161/cbt.11.2.14624

Loughran, T. P. J., & Wang, H. -G. (2011). Therapeutic Targeting of the Sphingolipid "Biostat" in Hematologic Malignancies. ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 11(9), 780-781.

Ren, T., Liu, X., Loughran, T. P., & Cheng, H. (2011). Developing T-LGL leukemia model for targeted therapy. CANCER RESEARCH, 71. doi:10.1158/1538-7445.AM2011-4304

Campbell, C., Zhang, R., Haley, J. S., Liu, X., Loughran, T., Schell, T. D., . . . Thakar, J. (2011). Why do CD8+T cells become indifferent to tumors: a dynamic modeling approach. FRONTIERS IN PHYSIOLOGY, 2. doi:10.3389/fphys.2011.00032

Iqbal, J., Weisenburger, D. D., Chowdhury, A., Tsai, M. Y., Srivastava, G., Greiner, T. C., . . . Chan, W. C. (2011). Natural killer cell lymphoma shares strikingly similar molecular features with a group of non-hepatosplenic γδ T-cell lymphoma and is highly sensitive to a novel aurora kinase A inhibitor in vitro. LEUKEMIA, 25(2), 348-358. doi:10.1038/leu.2010.255

Yu, J., Mitsui, T., Wei, M., Mao, H., Butchar, J. P., Shah, M. V., . . . Caligiuri, M. A. (2011). NKp46 identifies an NKT cell subset susceptible to leukemic transformation in mouse and human. JOURNAL OF CLINICAL INVESTIGATION, 121(4), 1456-1470. doi:10.1172/JCI43242

Clemente, M. J., Wlodarski, M. W., Makishima, H., Viny, A. D., Bretschneider, I., Shaik, M., . . . Maciejewski, J. P. (2011). Clonal drift demonstrates unexpected dynamics of the T-cell repertoire in T-large granular lymphocyte leukemia. BLOOD, 118(16), 4384-4393. doi:10.1182/blood-2011-02-338517

Saadatpour, A., Wang, R. -S., Liao, A., Liu, X., Loughran, T. P., Albert, I., & Albert, R. (2011). Dynamical and Structural Analysis of a T Cell Survival Network Identifies Novel Candidate Therapeutic Targets for Large Granular Lymphocyte Leukemia. PLOS COMPUTATIONAL BIOLOGY, 7(11). doi:10.1371/journal.pcbi.1002267

Watters, R. J., Liu, X., Fox, T. E., Kester, M., & Loughran, T. P. (2011). Targeting the sphingolipid pathway in NK large granular lymphocyte leukemia. CANCER RESEARCH, 71. doi:10.1158/1538-7445.AM2011-4302

Takahashi, Y., Meyerkord, C. L., Hori, T., Runkle, K., Fox, T. E., Kester, M., . . . Wang, H. -G. (2011). Bif-1 regulates Atg9 trafficking by mediating the fission of Golgi membranes during autophagy. AUTOPHAGY, 7(1), 61-73. doi:10.4161/auto.7.1.14015

Barth, B. M., Altinoglu, E. I., Shanmugavelandy, S. S., Kaiser, J. M., Crespo-Gonzalez, D., DiVittore, N. A., . . . Kester, M. (2011). Targeted Indocyanine-Green-Loaded Calcium Phosphosilicate Nanoparticles for In Vivo Photodynamic Therapy of Leukemia. ACS NANO, 5(7), 5325-5337. doi:10.1021/nn2005766

Liao, A., Broeg, K., Fox, T., Tan, S. -F., Watters, R., Shah, M. V., . . . Liu, X. (2011). Therapeutic efficacy of FTY720 in a rat model of NK-cell leukemia. BLOOD, 118(10), 2793-2800. doi:10.1182/blood-2011-01-331447

Lamy, T., & Loughran, T. P. J. (2011). How I treat LGL leukemia. BLOOD, 117(10), 2764-2774. doi:10.1182/blood-2010-07-296962

Talamo, G., Farooq, U., Zangari, M., Liao, J., Dolloff, N. G., Loughran, T. P., & Epner, E. (2010). Beyond the CRAB symptoms: a study of presenting clinical manifestations of multiple myeloma.. Clinical lymphoma, myeloma & leukemia, 10(6), 464-468. doi:10.3816/clml.2010.n.080

Liu, X., Ryland, L., Yang, J., Liao, A., Aliaga, C., Watts, R., . . . Loughran, T. P. J. (2010). Targeting of survivin by nanoliposomal ceramide induces complete remission in a rat model of NK-LGL leukemia. BLOOD, 116(20), 4192-4201. doi:10.1182/blood-2010-02-271080

Epling-Burnette, P. K., & Loughran, T. P. J. (2010). Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 19(5), 689-698. doi:10.1517/13543781003801076

Sekeres, M. A., List, A. F., Cuthbertson, D., Paquette, R., Ganetsky, R., Latham, D., . . . Maciejewski, J. P. (2010). Phase I Combination Trial of Lenalidomide and Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes. JOURNAL OF CLINICAL ONCOLOGY, 28(13), 2253-2258. doi:10.1200/JCO.2009.26.0745

Talamo, G., Barochia, A., Zangari, M., & Loughran, T. P. (2010). Multiple myeloma presenting as CEA-producing rectal cancer.. Rare tumors, 2(1), e4. doi:10.4081/rt.2010.e4

Abbi, K. K., Wagner, H., Drabick, J. J., Loughran, T. P., & Talamo, G. (2010). The role of radiation therapy for multiple myeloma in the era of novel agents. JOURNAL OF CLINICAL ONCOLOGY, 28(15). doi:10.1200/jco.2010.28.15_suppl.e18557

Abbi, K. K. S., Rizvi, S. M., Sivik, J., Thyagarajan, S., Loughran, T., & Drabick, J. J. (2010). Guillain-Barre syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: A case report and review of the literature. LEUKEMIA RESEARCH, 34(7), E154-E156. doi:10.1016/j.leukres.2010.02.036

Thomas, A., Perzova, R., Abbott, L., Benz, P., Poiesz, M. J., Dube, S., . . . Poiesz, B. J. (2010). LGL Leukemia and HTLV. AIDS RESEARCH AND HUMAN RETROVIRUSES, 26(1), 33-40. doi:10.1089/aid.2009.0124

Pastor, D. M., Eggers, A. D., Drabick, J. J., Loughran, T. P., Bayerl, M. G., & Shope, T. R. (2010). Retroperitoneal Diffuse Large B-Cell Lymphoma Presenting As Pseudoachalasia. JOURNAL OF CLINICAL ONCOLOGY, 28(12), E184-E187. doi:10.1200/JCO.2009.25.8715

Wozney, J. L., Damluji, A. A., Ahmed, F., Zangari, M., Loughran, T. P. J., & Talamo, G. (2010). Estimation of Daily Proteinuria in Patients with Multiple Myeloma by Using the Protein-to-Creatinine Ratio in Random Urine Samples. ACTA HAEMATOLOGICA, 123(4), 226-229. doi:10.1159/000313448